Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture
Authors:
- Vladimir TolmachevVladimir Tolmachev
- Anzhelika VorobyevaAVAnzhelika Vorobyeva
- Alia Hani Binti RoslyARAlia Hani Binti Rosly
- Javad GarousiJGJavad Garousi
- Yongsheng LiuYLYongsheng Liu
- Torbjörn GräslundTGTorbjörn Gräslund
- Eleftherios PapalanisEPEleftherios Papalanis
- Alexey SchulgaASAlexey Schulga
- Elena KonovalovaEKElena Konovalova
- Anna OrlovaAnna Orlova
- Sergey M. DeyevSDSergey M. Deyev
- Maryam OroujeniMaryam Oroujeni
Open Access
- 29 May 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5236
Abstract
Designed ankyrin repeat protein (DARPin) Ec1, a small scaffold protein (18 kDa), binds with high affinity the epithelial cell adhesion molecule (EpCAM) that is overexpressed in several carcinomas. To enhance the targeted delivery of cytotoxic drugs using Ec1, we investigated the potential of fusing Ec1 with an albumin-binding domain (ABD) to improve its circulation time and decrease renal uptake. Two fusion proteins were created, Ec1-ABD, with the ABD at the C-terminus, and ABD-Ec1, with the ABD at the N-terminus. Both variants were labeled with 111In. ABD-fused variants bound specifically to EpCAM-expressing cells with picomolar affinity. Adding human albumin reduced the affinity. This effect was more pronounced for Ec1-ABD; however, the affinity remained in the subnanomolar range. The position of the ABD did not influence the internalization rate of both variants by human cancer cells. In mouse models with human cancer xenografts, both variants demonstrated over 10-fold lower renal uptake compared to the Ec1. Tumor uptake of the ABD-fused variants was higher than the uptake of Ec1. ABD-Ec1 provided two-fold higher tumor uptake, indicating fusion with an ABD as a promising way to modulate the targeting properties of an Ec1-based construct. However, the effect of fusion depends on the order of the domains.Keywords
Funding Information
- Swedish Cancer Society (Cancerfonden) (20 0893 Pj, 20 0181 P, 23 0650 JIA, 23 2645 PjF 01H, 24 3883 Pj 01 H, 24 3523 Pj, UFV-PA 2022/3323, PG-22-0350-H-01, 2019-00986, 2023-02158, 2022-01519, 075-15-2024-536)
- Uppsala Universitet (20 0893 Pj, 20 0181 P, 23 0650 JIA, 23 2645 PjF 01H, 24 3883 Pj 01 H, 24 3523 Pj, UFV-PA 2022/3323, PG-22-0350-H-01, 2019-00986, 2023-02158, 2022-01519, 075-15-2024-536)
- Svenska Sällskapet för Medicinsk Forskning (20 0893 Pj, 20 0181 P, 23 0650 JIA, 23 2645 PjF 01H, 24 3883 Pj 01 H, 24 3523 Pj, UFV-PA 2022/3323, PG-22-0350-H-01, 2019-00986, 2023-02158, 2022-01519, 075-15-2024-536)
- Swedish Research Council (Vetenskapsrådet) (20 0893 Pj, 20 0181 P, 23 0650 JIA, 23 2645 PjF 01H, 24 3883 Pj 01 H, 24 3523 Pj, UFV-PA 2022/3323, PG-22-0350-H-01, 2019-00986, 2023-02158, 2022-01519, 075-15-2024-536)
- Ministry of Science and Higher Education of the Russian Federation (20 0893 Pj, 20 0181 P, 23 0650 JIA, 23 2645 PjF 01H, 24 3883 Pj 01 H, 24 3523 Pj, UFV-PA 2022/3323, PG-22-0350-H-01, 2019-00986, 2023-02158, 2022-01519, 075-15-2024-536)
This publication has 68 references indexed in Scilit:
- Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of PrincipleBiomaterials, 2021
- Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1International Journal of Biological Macromolecules, 2020
- Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumoursEuropean Journal of Pharmaceutics and Biopharmaceutics, 2019
- Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics2018
- Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor modelCancer Letters, 2016
- Challenges and opportunities for non-antibody scaffold drugsDrug Discovery Today, 2015
- Methods for Radiolabelling of Monoclonal Antibodies2013
- Epithelial cell adhesion molecule expression (CD326) in cancer: A short reviewCancer Treatment Reviews, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011